At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 180 enrolled
Drug / intervention
CM310 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CM310 in Adolescent Patients With Moderate-to-severe Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating CM310 and placebo for Atopic Dermatitis. Completed, enrolled 180 participants across 1 site.
Detailed Summary
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, pharmacokinetics(PK), pharmacodynamics(PD) and immunogenicity of CM310 in children patients with moderate-to-severe atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20252026
First PostedFeb 2024
Enrollment StartMar 2024
Primary CompletionJan 2025
TodayJul 2026
First PostedFeb 26, 2024
Enrollment StartMar 21, 2024
Primary CompletionJan 23, 2025
TodayJul 1, 2026
Enrollment to primary: 10 monthsPosted 2.3 years ago
Interventions
CM310biological
Interleukin-4 receptor(IL-4Rα) monoclonal antibody
placeboother
Placebo